Chetomin is reported to be an antibiotic metabolite of Chaetomium spp. which contains bacteriostatic effects on Gram-positive bacteria. Mechanistic studies suggest that Chetomin inhibits the division and separation of cells in cultures of B. fibrisolvens D1. Chetomin inhibits HIF (hypoxia-inducing factor) binding to the transcriptional coactivator p300. Chetomin disruption of HIF is believed to be done via a change in the structure of the CH1 domain of p300 which prevents interaction with HIF-1α and HIF-2α. Inhibition of this interaction has been reported to attenuate hypoxia-inducible transcription.
1. Jen, W.C. and Jones, G.A. 1983. Can. J. Microbiol. 29: 1399-1404. PMID: 6686488
2. Kung, A.L., et al. 2004. Cancer Cell. 6: 33-43. PMID: 15261140
3. Fujimoto, H., et al. 2004. J. Nat. Prod. 67: 98-102. PMID: 14738397
4. Staab, A., et al. 2007. BMC Cancer. 7: 213. PMID: 17999771
See how others have used Chetomin. Click on the entry to view the PubMed entry .
PMID: # 27271565 Fecher, RA. et al. 2016. J. Immunol. 197: 565-79.
PMID: # 24686084 Park, SH. et al. 2014. Cellular signalling. 26: 1506-13.
PMID: # 24398013 Park, JK. et al. 2014. Placenta. 35: 109-16.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.